The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of episodes of acute sickle cell disease (SCD) manifestations or pregnancy-related complications requiring acute health care encounters (acute care/ER/Hospital visits) or resulting in death over the entirety of pregnancy until 2 months post-partum in women with SCD. RBC transfusion is the only disease-modifying therapy for pregnant women with SCD, and it is considered a standard treatment option however, there exists no consensus on the role of transfusion therapy in preventing SCD-related pregnancy complications. Participants will be randomly assigned to repeated red blood cell transfusions or the standard of care. Participants will be on study for about 8-10 months (Pregnancy through 2 months post-partum).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Hospital admissions rate
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Number of maternal emergency department (ED)/Acute care visits
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Number of SCD-related complications per group
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Number of participants with pregnancy related complications
Timeframe: Baseline (enrollment) up to 8 weeks post-partum
Maternal death
Timeframe: From randomization up to 8 weeks post-partum